Author:
Chabert S,Saloppe X,Delaunoit B,Dupont G,Yengue P
Abstract
Introduction: Hepatitis C (HCV) is one of the major worldwide infections with 58 million infected persons in the world. HCV can lead to chronic liver disease, cirrhosis, and cancer. These past few years, clinical progress allowed a curative rate of 95% of the patients. There are still populations in which, treating the disease is more difficult, especially psychiatric patients, when substance abuse, psychiatric disorders are important risks factors for getting HCV. With the WHO organization establishing goals for clinical management and treatment of HCV, it is important to target where the difficulties lie in getting a better treatment program for those populations.
Aim: Try to highlight the challenges of treating a certain group of patients compare to the general population.
Method: This is a cross sectional monocentric study. 79 patients from a mental facility were included between 2012 and 2022. Inclusion criteria were: >18 years old, an active viral HCV infection.
Results: 34.7% of patients with a positive PCR were treated with a significant difference between the closed psychiatric unit and the open one (66.5 vs 22.6%, p<.05). There was an 82.4% eradication rate (Sustained Viral Response at 3 months). There were significantly more schizophrenic disorders in the closed unit and significantly more alcohol abuse in the open one.
Conclusion: Treatment of HCV in a psychiatric population is feasible with eradication rate equivalent at those in the general population. Patients with more severe mental illness are better treated in the configuration of a closed psychiatric unit.
Reference25 articles.
1. Global Health Sector Strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030 (no date) World Health Organization. Available at: https://www.who.int/publications/i/ item/9789240053779 (Accessed: 09 August 2023).
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). (American Psychiatric Pub, 2013).
3. IBM Corp. IBM SPSS statistics for Windows, version 27.0. Armonk, NY: IBM Corp (2020).
4. Drug-Drug Interaction Resources (no date) Liverpool University HIV/HEP/ Cancer Drug Interactions. Available at: https://www.druginteractions.org/ (Accessed: 09 August 2023).
5. CHASSER, Y., KIM, A.Y. AND FREUDENREICH, O. (2017) ‘Hepatitis C treatment: Clinical issues for psychiatrists in the Post-Interferon Era’, Psychosomatics, 58(1), pp. 1-10. doi:10.1016/j.psym.2016.09.004.